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Interstitial pneumonia associated with viral replication in lung tissue was observed after cytomegalovirus
infection of total-body y-irradiated mice, whereas in noncompromised hosts the lungs were not affected and
virus multiplication was restricted to the salivary glands. The radiation damage could either predispose
normally nonpermissive cell types for productive infection or abrogate an immune control of the tissue
manifestation of infection by elimination of lymphocytes. Adoptive transfer of lymphoid cells into irradiated,
infected recipients supported the second alternative. Even when infection was established in the lungs, as
manifested by the presence of infected lung tissue cells in the alveolar septa, an antiviral effect could be assigned
to the Lyt-2+, L3T4- subset ofT lymphocytes specifically sensitized in the immunocompetent donor. These cells
did not require in vitro propagation to perform effector cell functions in vivo and were operative under
physiological conditions in comparatively low numbers. Hence, there is reason to assume that T lymphocytes
are responsible for the tissue distribution of cytomegalovirus replication during infection.
In the therapeutic treatment of leukemia patients by
irradiation and bone marrow transplantation, a major com-
plication results from interstitial pneumonia associated with
reactivation of latent herpesviruses. In most cases viral
pneumonia with a very high incidence of mortality is due to
cytomegalovirus (CMV), whereas pneumonia associated
with herpes simplex virus or with varicella zoster is less
frequent and also less severe (30).
The experimental infection of mice with murine CMV
(MCMV) has proven an appropriate model to study CMV
pathogenesis since this infection of a natural host is also
linked with interstitial pneumonia (5, 19, 39). Like in the
infection of humans with human CMV, immunosuppression
is a prerequisite for MCMV reactivation from latency (13,
20, 29) and for infection of the lungs (5). These findings
indicate that the establishment of productive infection in the
tissues of the host is not only dependent on the virulence of
the virus and the presence of permissive cells but is also
controlled by the immune system.
During acute intraplantar MCMV infection of im-
munocompetent BALB/c mice, the presence of activated
interleukin (IL)-receptive cytolytic T-lymphocyte pre-
cursors (IL-CTLp) has been demonstrated in the draining
popliteal lymph node (LN) by measuring the lytic potential
of the IL-CTLp-derived effector CTLs after in vitro propaga-
tion mediated by IL only (34). In this combined protocol of
in vivo sensitization and in vitro propagation, Lyt-2+ CTLs
are generated that are able to recognize and destroy embry-
onic fibroblast target cells at a stage of viral replication when
only immediate-early proteins are expressed (35, 36). It has
been proposed that CTLs with such a specificity are candi-
dates to limit viral replication in infected tissues before the
production of progeny virions occurs (36).
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Adoptive transfer experiments have been applied to dem-
onstrate the in vivo potential of immune lymphoid popula-
tions (1, 17, 24, 26, 31, 41, 45, 47), as well as of CTL lines or
clones (8, 27, 28, 38), in various virus infections, including
the infection with MCMV (17, 41). Collectively, these stud-
ies have confirmed that mature, self-restricted Lyt-2+ CTLs
can exert an antiviral effect in vivo.
Provided that CTLs are also responsible for the preven-
tion of MCMV replication in the lungs of the immu-
nocompetent host during persistent infection, it follows that
sensitized CTLp do not require in vitro propagation to
mature to antiviral effector cells. This prediction can be
tested by direct adoptive transfer by using the infected
immunocompetent animal as donor of activated lympho-
cytes and the irradiated infected animal as recipient.
MATERIALS AND METHODS
Donors and recipients for adoptive transfer. BALB/c mice
(H-2d haplotype) were bred in our own colony and controlled
for the absence of murine hepatitis virus. To serve as donors
for sensitized lymphocytes, 8-week-old females were in-
fected in the left hind footpad with 105 PFU ofMCMV (strain
Smith, ATCC VR-194) grown in BALB/c mouse embryo
fibroblast cell culture and partially purified as described (34).
The stock used for priming contained 109 PFU ofMCMV per
ml in Ca- and Mg-free phosphate-buffered saline and was
controlled for absence of mycoplasma. To serve as recipi-
ents, female BALB/c mice at the age of 10 weeks were
subjected to total-body -y irradiation in a single dose of 6 Gy
(1 Gy = 1 J/kg = 100 rads) by using a cesium-137 source,
delivering a dose rate of 1.325 Gy/min. Infection was per-
formed as it was in the immunocompetent donors. There-
after, mice were kept under laminar flow.
Activated lymphocytes derived from the draining popliteal
LN of the donors 8 days after intraplantar infection were
suspended in 0.5 ml of 0.15 M NaCl supplemented with 1%
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BALB/c normal serum and injected into the tail vein of the
recipient. The time schedule for transfer depended on the
protocol intended. For the prophylactic transfer cells were
infused after irradiation and 2 h before infection, whereas for
the therapeutic transfer cells were infused 6 days postinfec-
tion (p.i.) when MCMV was already replicating in the lungs.
Treatment of donor cells for selection of T-lymphocyte
subsets. Complement-dependent antibody-mediated
cytolysis was applied to eliminate certain lymphocyte
subpopulations. The cells were treated with monoclonal
antibody (mAB) for 10 min at 4°C and low-toxicity rabbit
complement (diluted 1:15) for 45 min at 37°C in two cycles.
All mABs were used at their plateau activity as undiluted
hybridoma supernatants. Anti-Lyt-2.2 mAB (im-
munoglobulin G2a) was produced by hybridoma 19/178 (16).
To deplete for L3T4+ lymphocytes, mAB GK1.5 (im-
munoglobulin G2b) was used (10).
To prove the efficiency of depletion of L3T4+ lympho-
cytes, normal splenocytes were treated either with mAB
GK1.5 and complement or, for control, with complement
alone. Thereafter, 5 x 106 cells per ml of minimal essential
medium a were incubated for 20 h in the presence of 10 jig
of the T-cell mitogenic lectin concanavalin A (Pharmacia,
Uppsala, Sweden). Minimal essential medium a without
nucleosides (GIBCO Laboratories, Grand Island, N.Y.) was
supplemented with 5% fetal calf serum, 2 mM L-glutamine,
and 5 x 10-5 M 2-mercaptoethanol. The IL-2 content of the
culture supernatant was then assessed with a nonhelper
subline (21) of the IL-2-dependent BALB/c-derived T-cell
line HT-2 (44) and was found to be 10% of the control value.
Bone marrow cell populations obtained by flushing me-
dium through the shafts of the femori and tibiae of normal
BALB/c mice were depleted for cells of the T-cell lineage by
using a mixture of the mABs anti-Lyt-2.2 and GK1.5. Before
intravenous infusion, all cell suspensions were passed
through nylon mesh to remove clumps.
Determination of tissue virus titers and statistical evalua-
tion. Organs were frozen, thawed, and passed for homogeni-
zation through stainless steel mesh in minimal essential
medium with Earle salts (Serva) supplemented with 5% fetal
calf serum, 2 mM L-glutamine, 10 mM HEPES (N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer
(pH 7.2), 100 U of penicillin per ml, 0.1 mg of streptomycin
sulphate per ml, 0.2 mg of gentamycin per ml, and 2.5 ,ug of
amphotericin B per ml. The homogenates were titrated in
logl0 dilutions on subconfluent second-passage mouse em-
bryo fibroblasts in 48-well culture plates (Costar, Cam-
bridge, Mass.), starting with an 0.5% sample of the homog-
enate of the lungs, salivary glands, and spleen and an 0.05%
sample of the liver. Usually, each dilution was represented
by two replicate cultures. Only when titers were expected to
be low was the highest concentration tested in four repli-
cates, thereby defining the detection level as 500 PFU for the
liver and 50 PFU for the other organs. The pooled parotid,
greater sublingual, and mandibular glands are collectively
referred to as salivary glands.
To enhance the sensitivity of the assay, infection was
performed under the influence of a centrifugal field of 800 x
g for 30 min (18). Thereafter, monolayers were washed and
covered with methylcellulose, and plaques were counted 4
days later.
The distribution-free exact rank sum test (Wilcoxon-
Mann-Whitney test) was applied to compare independent
sets of data (2). This test is indicated when a normal
distribution of data can not be considered as proven. The
null hypothesis of similar location is rejected, and the
alternative hypothesis of dissimilar location is accepted for P
< a = 0.05, where P denotes the observed probability value
and a denotes the selected significance level.
Light and electron microscopy. For light microscopy lungs
derived from irradiated, infected mice were fixed with Bouin
fixative. Tissue samples were embedded in paraffin, and thin
sections (5 ,um) were stained with hematoxylin and eosin.
For electron microscopy fixation was performed with 2.5%
glutaraldehyde buffered at pH 7.2 with 0.1 M sodium
cacodylate. After postfixation in 1% osmium tetroxide,
tissue blocks were embedded in araldite. Thin sections (1
,um) were stained with toluidine blue to select sites of
interest by light microscopy. Ultrathin sections from se-
lected regions were stained with uranyl acetate and lead
citrate and then examined with a Siemens 101 electron
microscope.
In situ hybridization of lung tissue sections with cloned
MCMV DNA fragments. Microtome thin sections (5 to 10
,um) of frozen lung tissue were spread on pretreated slides (3)
and processed for hybridization by published procedures (4).
The hybridization solution (15) contained 0.5 ng of plasmid
cloned MCMV DNA HindIII fragments A, B, D, and C per
IlI (11, 22) tritiated by nick translation (37) to a specific
activity of 4 x 107 dpm/,g. After hybridization at 37°C for 24
h the specimens were washed at 37°C for 5 min three times
in 50% formamide-3x SSC (lx SSC is 0.15 M NaCl plus
0.015 M sodium citrate) and for 60 min three times in 3 x
SSC, dehydrated, coated for autoradiography with NTB 3
photoemulsion (Eastman Kodak Co., Rochester, N.Y.) and
exposed for 3 days at 4°C.
Lungs
ic is
c 6-
cm
0
5- 5-
5
._U4--
0
o
a 2D
-- DL
Spleen
iC is
Liver Slivry cand
iC is iC is
±
t t
--(0)
(0)----
FIG. 1. Effect of irradiation on the tissue manifestation of
MCMV infection. Virus titers were measured in the indicated
tissues of five immunocompetent (ic) and five immunosuppressed
(is) BALB/c mice 14 days after intraplantar infection with 10, PFU
of MCMV. Immunosuppression was achieved by total-body y
irradiation with a single dose of 6 Gy. The median values of the
individual titer determinations are marked by horizontal bars. The
dashed line represents the experimental detection level (DL) that
was defined as 500 PFU for the liver and 50 PFU for the other
organs. The arrows indicate that titers were below DL.
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FIG. 3. Coincidence of mortality and increase in lung tissue virus titers. Forty 10-week-old female BALB/c mice were subjected at day
zero to y irradiation with a single dose of 6 Gy (equal to a lethal dose causing 50%o of the mice to die within 30 days), followed by intraplantar
infection with 105 PFU ofMCMV. Thereafter, two groups were formed by distributing the mice randomly. The kinetics of virus multiplication
in the lungs was measured in one group (the mean titer of two random samples is depicted), and the incidence of death was monitored in the
second group (the bars represent numbers of deceased animals for each day). In infected but not irradiated controls 0 of 20 mice died, whereas
in irradiated but not infected controls 11 of 20 mice died within the observation period of 30 days. The arrowheads mark the virus titers at
day 6 and day 14, which are important for the subsequent experimental schedules.
RESULTS
Effect of -y irradiation on the tissue manifestation of infec-
tion. In immunocompetent donors, footpad infection elicited
a marked cellular immune response in the draining popliteal
LN, as indicated by an increase in cell numbers from 106 to
2 x 107 within 8 days and a frequency of activated MCMV-
specific CTLp in the order of lo-3 to 1i-' depending on the
in vitro propagation protocol applied (34). When 105 PFU of
cell culture-grown MCMV was used for infection, no signs of
inflammation were detectable at the site of infection, nor
could infectious virus be recovered at day 14 p.i. from
organs such as lungs, spleen, or liver, although infectious
virus was recovered from the salivary glands, which are a
privileged site for MCMV replication during persistency
(Fig. 1). Accordingly, MCMV, formerly named salivary
gland virus of the mouse, has originally been isolated from
persistently infected salivary glands (40).
On the contrary, in 6-Gy fy-irradiated recipients, im-
munosuppression was manifested by a decline in the cell
numbers of the popliteal LN from 106 to 104 within 8 days
and the absence of activated MCMV-specific CTLp after
infection (data not shown). In the footpad, a highly exuda-
tive process with extensive hemorrhages and local necrosis
was seen histologically at day 14 p.i. (F. Weiland, manu-
script in preparation), and high virus titers were observed
not only in the salivary glands but also in liver, spleen, and
lungs (Fig. 1).
Evidence for interstitial pneumonia. To establish a model
for viral pneumonia, it had to be verified that virus detected
in the lungs of the immunosuppressed host is autochtonously
replicating in lung tissue and is not just disseminated from
the salivary glands. Histological studies demonstrated symp-
toms of a moderate focal interstitial pneumonia: cell swell-
ing, exudation of fluid into interstitial areas, and cells located
in the widened alveolar septa containing intranuclear inclu-
sions (Fig. 2a). The etiology of this infection was confirmed
by in situ hybridization (Fig. 2b) by using plasmid cloned
MCMV DNA fragments (11, 22). With this highly specific
and sensitive technique, infected cells could be detected in
lung tissue at day 6 p.i., and thereby it was proved that
infection was established at that time (Fig. 2c). Electron
FIG. 2. Histological evidence for established infection of lung tissue. Lung tissue was derived at day 14 p.i. (panels a, b, and d) or at day
6 p.i. (panel c) from BALB/c mice infected in the footpad with 105 PFU ofMCMV after immunosuppression by total-body -y irradiation with
a single dose of 6 Gy. (a) Thin section of lung tissue stained with hematoxylin and eosin and examined by light microscopy (magnification,
x 160), demonstrating the widening of the alveolar septa and a cell bearing a typical intranuclear inclusion (arrow). (b and c) Infected cells
in cryostat thin sections of frozen lung tissue were detected at day 14 p.i. (b) and at day 6 p.i. (c) by in situ hybridization of viral nucleic acid
with a mixture of plasmid cloned MCMV DNA HindIll fragments as specific probe. Autoradiographs were exposed for 3 days and examined
by light microscopy (magnification, x 160). Infected cells were located in the alveolar septa (arrows). (d) Electron micrograph (magnification,
X15,000) showing an infected interstitial fibroblastic cell producing collagen (asterisk). This cell is covered with a rim of thin flattened
cytoplasm extruding from a membraneous pneumocyte (opposed arrowheads), Nucleocapsids can be detected in the nucleus (arrowhead),
monocapsid virions in the perinuclear cisterna (small arrows), and multicapsid virions in the extracellular space (large arrows).
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FIG. 4. Differential antiviral efficiency of activated donor lymphocytes in the tissues of cell transfer recipients. Irradiated animals received
specifically activated donor lymphocytes by intravenous infusion before intraplantar infection. At day 14 p.i. MCMV titers were measured
in the organs of five recipients for each dose of transferred lymphocytes. The median values of the individual titer determinations are shown
by horizontal bars. The dashed lines represent the detection levels (DL).
microscopic analysis identified interstitial cells (Fig. 2d),
pneumocytes, and endothelial cells (data not shown) as the
target cells for MCMV replication in lung tissue after irradia-
tion when cellular infiltration was virtually absent. After
immunosuppression of mice by treatment with antilympho-
cyte antiserum, MCMV has been shown to replicate also in
pulmonary macrophages (5).
The dying of the irradiated, infected animals coincided
with a log-linear increase in tissue virus titers, as exemplified
for the lungs (Fig. 3). The virus titer observed in the liver
(Fig. 1 and 4) was due to infection of hepatocytes causing
focal necrosis (data not shown), and in addition other
essential organs may be affected.
Prophylactic adoptive transfer of specifically activated lym-
phocytes. This type of transfer protocol was applied for
probing the capacity of in vivo-sensitized lymphocytes to
prevent the tissue manifestation of the MCMV infection.
The lymphocytes were taken from the draining popliteal LN
of immunocompetent donors (BALB/c mice, H-2d
haplotype) infected in the footpad 8 days previously and
were transferred intravenously into irradiated syngeneic
recipients that were infected in the footpad 2 h after cell
transfer. The read-out time for the virus titers in the organs
was defined as 14 days p.i. at the peak of mortality in the
nonreconstituted control group (Fig. 3). From the results
depicted in Fig. 4, the following information can be deduced.
First, a significant antiviral effect in the lungs (P = 0.005;
one-sided distribution-free Wilcoxon-Mann-Whitney test),
liver (P = 0.01), and spleen (P = 0.025) can be established
after transfer of only 104 activated lymphocytes (i.e., <0.1%
of the lymphocyte content of a single donor LN). This
number of activated lymphocytes contains ca. 103 Lyt-2+
lymphocytes, as revealed by fluorescent-activated cell sorter
analysis (data not shown) and within this subset ca. 10
sensitized MCMV-specific CTLp (34). Second, prevention of
detectable MCMV replication in the tissues is mediated by
105 activated lymphocytes in the case of the liver and spleen
(in four of five recipients the virus titer did not exceed the
detection level) and by 106 activated lymphocytes in the case
of the lungs. Third, although lymphocytes proved to be
effective in preventing viral replication in certain tissues that
are relevant for pathogenesis, even 107 transferred activated
lymphocytes were not sufficient to clear the MCMV infec-
tion since viral replication persisted in the salivary glands-
again underlining the exceptional role of the salivary glands
in CMV infections. The tissue distribution of viral replica-
tion after transfer of 107 activated lymphocytes closely
resembled that displayed by the infected immunocompetent
host (compare Fig. 1 and 4), and accordingly all recipients
survived.
Clinical trials in the therapy of leukemia involve re-
constitution with type-matched bone marrow after total-
body or total-lymphoid irradiation (30). In this context it is
important to note that transfer of up to 107 syngeneic bone
marrow cells which were depleted for Lyt-2+ and L3T4+
cells of the T-cell lineage had no significant effect on the
virus titers in the lungs (P > 0.2 when virus titers in the lungs
of control mice that did not receive bone marrow cells were
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FIG. 5. Specifically activated lymphocytes limit virus multiplication during established infection of the lungs. The experimental schedule
for therapeutic adoptive transfer is delineated. For the control, virus titers were determined in nonreconstituted hosts at day 6 p.i., the time
of transfer (column A), and at day 14 p.i. (column B). Bone marrow cells were depleted for cells carrying the T-cell markers Lyt-2.2 and L3T4
by treatment with the corresponding antibodies (anti-Lyt-2.2 and GK1.5) and complement (column C). Activated lymph node lymphocytes
(LN-Ly) were derived from popliteal LN of donors infected in the footpad with 10i PFU of MCMV 8 days previously (column D), and
noninfected mice served as donors for nonimmune popliteal lymph node lymphocytes (column E). The virus titers in the lungs of five
recipients for each group are depicted, and the median values are indicated by horizontal bars.
compared at day 14 p.i. with titers measured in lungs of
reconstituted mice; two-sided Wilcoxon-Mann-Whitney
test). In the same period of time the spleen was repopulated
by the transferred bone marrow cells, as manifested by
enlargement of the spleen, increase in leucocyte content
from 1.2 x 106 to 50.1 x 106 (median values for five transfer
recipients each), and the typical development of reconstitu-
tion nodules.
Therapeutic adoptive transfer of specifically activated lym-
phocytes. The therapeutic adoptive transfer is a means to
investigate the question of whether activated lymphocytes
can limit viral replication in the lungs even during estab-
lished infection of the tissue. MCMV-infected cells were
detectable in the lungs at day 6 p.i. (Fig. 2c), when four of
five animals were virus positive, showing MCMV titers of
only 102 to 103 PFU (Fig. 3; resolved to greater detail in Fig.
5, column A). Taking into account that ca. 50 PFU per cell
can be recovered from productively infected fibroblasts in
vitro (data not shown) and assuming a similar burst size in
vivo, an observed virus titer of 103 PFU corresponds with
ca. 20 producing cells in the lungs. Interference with viral
replication at such a germinal stage of lung tissue infection
should retard the log-linear increase in virus titers. Accord-
ingly, transfers were performed at day 6 p.i., and as was the
case for the prophylactic transfer, the virus titers were
determined at day 14 p.i. (Fig. 5). Under these conditions,
syngeneic bone marrow transplantation was again inefficient
with respect to the control of lung tissue infection (P > 0.1;
compare columns B and C), whereas transfer of 106 acti-
vated lymphocytes (column D) confined the increase in virus
titers (significant [P = 0.005]) to <5% of the positive control
values (columns B, C, and E), resulting in an absolute
difference in virus load of >105 PFU. This antiviral effect
was evidently mediated by lymphocytes sensitized in the
infected donors, since transfer of the same amount of resting
lymphocytes derived from popliteal LN of nonimmune do-
nors was not effective (P = 0.1; compare columns B and E).
Absence of specific antibody in transfer recipients. To
evaluate a possible contribution of antiviral antibody in the
control of tissue manifestation of MCMV infection after
therapeutic transfer, the antibody titer in the serum of the
recipients (the same animals as shown in Fig. 5, column D)
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FIG. 6. T lymphocytes of the Lyt-2+, L3T4- subset limit virus multiplication during established pulmonary MCMV infection. Therapeutic
adoptive transfer of 106 subset-selected specifically activated lymph node lymphocytes (LN-Ly) was performed according to the schedule
outlined in Fig. 5. Donor lymphocyte populations were depleted for distinct T-lymphocyte subsets by two cycles of treatment with mAB
anti-Lyt-2.2 and complement (column C) or with mAB GK1.5 (anti-L3T4a) and complement (column D). The median values of the virus titers
determined in the lungs of five recipients for each experimental group are marked by horizontal bars. The distribution-free Wilcoxon-Mann-
Whitney test (rank sum test, one-sided) was applied to evaluate the significance of differences between independent sets of virus titers: P
(columns A and B) = 0.005; P (columns B and C) = 0.005; P (columns C and D) = 0.005; P (columns A and D) = 0.005; P (columns A and
C) > 0.1; and P (columns B and D) > 0.1.
was monitored by an enzyme-linked immunosorbent assay
at day 8 posttransfer. There was no indication of a role for
sensitized B lymphocytes at the early stages of reconstitu-
tion, since MCMV-specific antibody could not be detected in
the recipients, whereas latently infected mice, inoculated
with MCMV as newborns, proved to be seropositive (data
not shown).
Serological characterization of cells that limit viral replica-
tion in the lungs. Before therapeutic adoptive transfer into
irradiated and infected recipients, the activated donor lym-
phocytes were preselected for distinct subsets by comple-
ment-dependent cytolysis with mABs to the cell surface
antigens Lyt-2.2, preferentially expressed by class I major
histocompatibility complex antigen-restricted T lympho-
cytes (42), or L3T4, specific for most class II major
histocompatibility complex antigen-restricted T lympho-
cytes (10, 33) (Fig. 6). These markers appear not to be
coexpressed on mature T lymphocytes (10, 33), whereas
both are present on immature thymocytes (9, 10). Treatment
with mAB GK1.5, specific for the L3T4a determinant (10),
did not significantly affect the ability of the population to
limit viral replication (P > 0.1; compare columns B and D),
whereas in a control experiment the lectin-induced produc-
tion of IL-2 by splenocytes was reduced to 10%, indicating
that IL-2-producing helper T lymphocytes can be eliminated
by the protocol applied (data not shown; for details see
above). On the other hand, depletion of the transferred
population for Lyt-2+ lymphocytes, predominantly repre-
senting CTL and their precursors, abrogated the antiviral
effect in lung tissue (significant [P = 0.005]; compare col-
umns B and C). By screening a series of thin sections from
lungs of transfer recipients, it was found that histopathologi-
cal alterations and the frequency of infected cells that bear
the characteristic intranuclear inclusion were reduced only
when Lyt-2+ lymphocytes were present in the transferred
population. In conclusion, the Lyt-2', L3T4- subset of
sensitized donor T lymphocytes can control MCMV replica-
tion in the lungs.
DISCUSSION
Infection of the lungs with MCMV is not observed in the
noncompromised host but occurs after total-body y irradia-
tion. Radiation could either predispose lung tissue for pro-
ductive MCMV infection by altering the permissivity of cells
or abrogate an immune control of virus replication by
eliminating antiviral lymphocytes. A therapeutic effect of
transferred lymphocytes directly derived from infected, im-
munocompetent donors would indicate that the second of
the proposed mechanisms is a relevant one.
The present study allows the following conclusions. First,
lymphocytes sensitized in vivo during infection of an im-
munocompetent host have an antiviral effect when trans-
ferred into irradiated and thereby immunosuppressed, in-
J. VIROL.
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fected recipients. This finding implies either that the donor
LN already contain effector cells or that sensitized pre-
cursors mature to effector cells in the recipient due to
secondary encounter with antigen.
Second, activated lymphocytes are effective in a therapeu-
tic adoptive transfer when infection of the lungs is already
established, suggesting that they can operate in the affected
tissue. Under the conditions tested neither bone marrow
cells nor nonactivated lymphocytes were efficient with re-
spect to the control of virus replication in the lungs, demon-
strating that a property acquired in the infected donor is
measured.
Third, the therapeutic antiviral effect of sensitized lym-
phocytes during established infection of lung tissue can be
assigned to the Lyt-2+, L3T4- subset of T lymphocytes.
This result implies that natural killer cells which do contrib-
ute to the defense against MCMV early in acute infection (6,
7) were either not contained in sufficient numbers in the
transferred populations or not operative under the condi-
tions of the therapeutic transfer protocol applied. Recent
studies on the Lyt phenotype of T lymphocytes that affect
virus multiplication during acute infections have demon-
strated that cloned Lyt-1-2+ CTLs can operate in adoptive
transfer experiments (8, 27, 28). In herpes simplex virus
infection, the antiviral effect of transferred acutely sensitized
lymphocyte populations has been assigned to the Lyt-1+2-
subset (24). Besides cloned Lyt-1-2+ CTLs, cloned Lyt-
1+2+ CTLs have been shown to be active in allogeneic tumor
rejection (12), and a role of Lyt-1+2+ lymphocytes in the
control of viral infection has also been suggested (43).
Sensitized Lyt-1+2+ lymphocytes represent the majority of
the IL-receptive IL-CTLp present in draining LN during
acute MCMV infection (34) and hence are contained in the
donor lymphocyte population tested in our adoptive transfer
experiments. Since the differences in Lyt-1 antigen expres-
sion between subsets of T lymphocytes are only quantitative(25), use of the mutually exclusive and hence discriminative
markers Lyt-2 and L3T4 (10, 33, 42) was indicated to
characterize the T-lymphocyte subset that is operative in
vivo in a particular experimental situation. Clearly, interfer-
ence with MCMV replication in an established infection of
the lungs is a function of Lyt-2', L3T4- T lymphocytes.
By using the limiting dilution assay, the minimum estimate
for the frequency of in vivo-activated MCMV-specific CTLp
was found to be in the order of 103 per 106 LN lymphocytes
(34) or 103 per 105 Lyt-2+ LN lymphocytes. After prophy-
lactic transfer, 104 lymphocytes containing an estimated
number of only ca. 10 specifically sensitized CTLp were able
to diminish virus titers in several organs. As demonstrated
for the lungs, infected cells were first detectable in low
numbers in target tissue at day 6 p.i., indicating that even in
the immunosuppressed host the spread of virus from the
local site of intraplantar infection to target organs occurs
with low efficiency and is likely to be very sensitive to
early-operating adopted immune surveillance. Therefore, in
the prophylactic transfer protocol, effector cells most prob-
ably act by affecting the spread of virus to target organs
rather than by eliminating infected cells in various target
tissues. Accordingly, when at day 6 p.i. the infection was
established in target tissue, 100-fold more cells had to be
transferred to cope with virus multiplication.
Besides mediating direct cytolysis of infected cells, CTLs
could also operate by producing lymphokines (14, 46).
Evidence in favor of direct in vivo cytolysis has been
presented recently for influenza A virus infection (28), and
arguments against direct in vivo cytolysis have been dis-
cussed for infection with lymphocytic choriomeningitis virus
(26). Our data do not disfavor either of these theories.
According to a recent report, the spread of established
pulmonary sarcoma metastases could be inhibited only when
high numbers of in vitro lymphokine-activated killer cells
and high doses of recombinant IL-2 were administered in
combination (32). Compared with this tumor model, the
established pulmonary MCMV infection appears to be more
accessible to immune surveillance since significant interfer-
ence with viral replication was achieved with comparatively
low numbers of in vivo-sensitized Lyt-2+, L3T4- T lympho-
cytes without in vitro restimulation and without application
of IL-2. Experiments are in progress to test whether the
therapeutic effect of transferred MCMV-specific lympho-
cytes can be enhanced by IL-2.
CMV specify a multitude of polypeptides, and it would be
of interest to know against which viral or virus-induced
antigens the cellular immune response is directed. It has
been shown that MCMV replication stage-specific CTLs can
be distinguished that recognize target cells carrying viral
structural proteins or expressing a lymphocyte-detected
immediate-early antigen (35). Although only one major im-
mediate-early protein is synthesized in infected cells (23), a
high number of activated CTLp present in the draining LN
after infection were found to be specific for lymphocyte-
detected immediate-early antigen (36), suggesting that this
antigen is immunodominant.
Virus replication in the lungs of irradiated hosts after
therapeutic transfer of CTL lines or clones specific for
lymphocyte-detected immediate-early antigen or other anti-
gens specified by MCMV provides a relevant parameter to
test the functional competence of CTLs with different speci-
ficities and to evaluate the implication of particular antigens
in immune surveillance during acute, persistent, and latent
CMV infection.
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